Business
Admission of Further Securities to Trading
AstraZeneca PLC has announced the admission of 14,784 further ordinary shares of $0.25 each to trading on the London Stock Exchange's Main Market. These shares, fully fungible with existing ordinary shares, were issued between June 1 and June 30, 2026, under a block admission dated January 29, 2021, and are part of the company's employee share schemes. Following this admission, the total number of ordinary shares in issue now stands at 1,551,024,534. Disclaimer*
About this update from Astrazeneca Plc
1 July 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R. 1 Details of the issuer a) Name AstraZeneca PLC b) LEI PY6ZZQWO2IZFZC3IOL08 2 Details of the transferable securities admitted to trading a) Name, type and identification code Ordinary Shares of $0.25 each ISIN: GB0009895292 b) Regulated market London Stock Exchange - Main Market c) Number of further securities issued and admitted 14,784 d) Total number of securities in issue following admission 1,551,024,534 e) Fungibility Fully fungible with existing Ordinary Shares 3 Admission details a) Date of admission Issued between 1 June 2026 to 30 June 2026 (admitted under a block admission dated 29 January 2021) b) Prospectus information Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com c) Coverage of notification Admission of shares under the Company's employee share schemes from 1 June 2026 up to 30 June 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. Matthew Bowden Company Secretary AstraZeneca PLC